Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region - A open labelled single arm phase II study

Dattatreya, Satya; Goswami, Chanchal

doi:10.4103/0019-509x.82873

Cited by 16 publications

(16 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, radiotherapy combined with cetuximab can be seen as alternative treatment option for specific cases but seems not superior to standard radiochemotherapy [33,34,35]. Some studies showed moderate improvements of local control and long-term survival after treatment with cetuximab plus radiotherapy [36,37]. Results of triple combination in randomized trials have preliminarily been reported and do also not support superiority over radiochemotherapy [38,39].…”

Section: Cetuximab Combined With Radiotherapymentioning

confidence: 99%

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

et al. 2014

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular target for the treatment of different cancer entities. In this regard, the anti-EGFR antibody cetuximab has been approved alone or in combination with: (a) chemotherapy for treatment of colorectal and head and neck squamous cell carcinoma and (b) with external radiotherapy for treatment of head and neck squamous cell carcinoma. The conjugation of radionuclides to cetuximab in combination with the specific targeting properties of this antibody might increase its therapeutic efficiency. This review article gives an overview of the preclinical studies that have been performed with radiolabeled cetuximab for imaging and/or treatment of different tumor models. A particularly promising approach seems to be the treatment with therapeutic radionuclide-labeled cetuximab in combination with external radiotherapy. Present data support an important impact of the tumor micromilieu on treatment response that needs to be further validated in patients. Another important challenge is the reduction of nonspecific uptake of the radioactive substance in metabolic organs like liver and radiosensitive organs like bone marrow and kidneys. Overall, the integration of diagnosis, treatment and monitoring as a theranostic approach appears to be a promising strategy for improvement of individualized cancer treatment.

show abstract

Section: Cetuximab Combined With Radiotherapymentioning

confidence: 99%

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Dattatreya and Goswami [12] observed an overall response rate (ORR) of 68.42% and a 2-year OS of 84% in 19 unresectable patients treated with BRT, as in Bonner et al's trial [9]. At 2 years, 13 patients remained without progression.…”

Section: Resultsmentioning

confidence: 97%

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Granados-García

Aguilar-Ponce²,

Maldonado-Magos³

et al. 2016

ORL

View full text Add to dashboard Cite

We review clinical trials of squamous cell carcinoma of the head and neck (SCCHN) to address the current and potential uses of cetuximab (CTX). PubMed was reviewed to identify papers published between 2010 and 2016. The search terms used were “cetuximab” and “head and neck cancer.” A total of 634 articles were identified. Phase II or III studies with CTX in patients with advanced SCCHN without treatment or with recurrent/metastatic tumors were selected. Forty-six registries were obtained. Information was critically reviewed and relevant information presented. As definitive treatment of advanced squamous cells carcinomas and as palliative treatment of recurrent/metastatic disease, CTX alone or associated with chemotherapy and/or radiotherapy is an alternative to chemoradiotherapy because of its distinct and favorable toxicity profile.

show abstract

“…By the time the study was published, concomitant CTRT had become the standard of care for unresectable HNSCC. Dattatreya, et al 6 recorded 19 unresectable patients treated with CTX/RT, with Bonner's scheme, and observed overall responses (OR) of 68.42% and two-year OS of 84%. Two years after the protocol was concluded, 13 patients remained free of progression.…”

Section: Discussionmentioning

confidence: 99%

Multidisciplinary, Multi-Institutional Consensus on Cetuximab Usefulness in the Treatment of Patients with Head and Neck Squamous Cell Carcinoma

Barrera-Franco¹,

Bautista-Aragón²,

Gallegos-Hernández³

et al. 2022

GAMO

View full text Add to dashboard Cite

Epidermal growth factor receptor is preferably expressed in head and neck squamous cell carcinomas and is a promising therapeutic target. Cetuximab is the only epidermal growth factor receptor-targeted agent that has been approved for the treatment of squamous cell carcinoma. The 2006 FDA-approved indication refers to the use of cetuximab in combination with radiotherapy for the treatment of locoregional, advanced, unresectable head and neck squamous cell carcinoma, except for nasopharyngeal carcinoma. In 2011, the use of cetuximab in combination with platinum and 5-fluorouracil was approved as first-line treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. In order to homogenize and arrive at a multidisciplinary, multi-institutional consensus based on scientific evidence, a meeting was held where the existing literature was reviewed and the role of cetuximab in the treatment of patients with head and neck squamous cell carcinoma was discussed. This work reviews current evidence-based indications for the use of cetuximab in the treatment of patients with head and neck squamous cell carcinoma. (creativecommons.org/ licenses/by-nc-nd/4.0/).

show abstract

Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region - A open labelled single arm phase II study

Abstract: Cetuximab concurrent with radiotherapy is a safe and effective option in advanced head-neck cancer patients.

Cited by 16 publications

References 4 publications

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Multidisciplinary, Multi-Institutional Consensus on Cetuximab Usefulness in the Treatment of Patients with Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About